Search Page

1

Cite

Share

Heyde's syndrome without a decrease in large von Willebrand factor multimers: a case of intestinal bleedings reversed by valve replacement in a patient with aortic stenosis.

Undas A, Windyga J, Bykowska K, Dimitrow PP, Stepien E, Sadowski J. Undas A, et al. Among authors: windyga j. Thromb Haemost. 2009 Apr;101(4):773-4. Thromb Haemost. 2009. PMID: 19350125 No abstract available.

Cite

Share

2

Cite

Share

Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.

Windyga J, von Depka-Prondzinski M; European Wilate® Study Group. Windyga J, et al. Thromb Haemost. 2011 Jun;105(6):1072-9. doi: 10.1160/TH10-10-0631. Epub 2011 Mar 24. Thromb Haemost. 2011. PMID: 21437358 Clinical Trial.

Cite

Share

3

Cite

Share

Total elbow arthroplasty in patient with severe von Willebrand disease.

Kotela I, Zbikowski P, Ambroziak P, Buczma A, Gwozdowska A, Kotela A, Windyga J. Kotela I, et al. Among authors: windyga j. Haemophilia. 2014 Nov;20(6):e441-3. doi: 10.1111/hae.12555. Epub 2014 Oct 2. Haemophilia. 2014. PMID: 25274268 No abstract available.

Cite

Share

4

Cite

Share

Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.

Berntorp E, Windyga J; European Wilate Study Group. Berntorp E, et al. Among authors: windyga j. Haemophilia. 2009 Jan;15(1):122-30. doi: 10.1111/j.1365-2516.2008.01901.x. Haemophilia. 2009. PMID: 19149848 Clinical Trial.

Cite

Share

5

Cite

Share

Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.

Powell J, Martinowitz U, Windyga J, Di Minno G, Hellmann A, Pabinger I, Maas Enriquez M, Schwartz L, Ingerslev J; LipLong Study Investigators. Powell J, et al. Among authors: windyga j. Thromb Haemost. 2012 Nov;108(5):913-22. doi: 10.1160/TH12-03-0188. Epub 2012 Sep 26. Thromb Haemost. 2012. PMID: 23014711 Clinical Trial.

Cite

Share

6

Cite

Share

Use of objective efficacy criteria for evaluation of von Willebrand factor/factor VIII concentrates.

Kessler CM, Windyga J, Schwartz BA, Knaub S. Kessler CM, et al. Among authors: windyga j. Blood Coagul Fibrinolysis. 2012 Jun;23(4):262-7. doi: 10.1097/MBC.0b013e3283504118. Blood Coagul Fibrinolysis. 2012. PMID: 22322140

Cite

Share

7

Cite

Share

Inhibitor development in non-severe haemophilia across Europe.

Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M; EUHASS Participants. Fischer K, et al. Among authors: windyga j. Thromb Haemost. 2015 Oct;114(4):670-5. doi: 10.1160/TH14-12-1044. Epub 2015 Aug 13. Thromb Haemost. 2015. PMID: 26293381

Cite

Share

8

Cite

Share

Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.

Klukowska A, Windyga J, Batorova A. Klukowska A, et al. Among authors: windyga j. Thromb Res. 2011 Mar;127(3):247-53. doi: 10.1016/j.thromres.2010.11.030. Epub 2011 Jan 8. Thromb Res. 2011. PMID: 21220152

Cite

Share

9

Cite

Share

Severe bleeding due to hypersensitivity to vitamin K antagonist caused by the c.109G>A (p.Ala37Thr) mutation in the F9 gene in a patient with mechanical heart valve prosthesis.

Odnoczko E, Falkowska J, Baran B, Buczma A, Stefanska-Windyga E, Windyga J. Odnoczko E, et al. Among authors: windyga j. Thromb Res. 2019 Feb;174:59-61. doi: 10.1016/j.thromres.2018.12.005. Epub 2018 Dec 12. Thromb Res. 2019. PMID: 30576981 No abstract available.

Cite

Share

10

Cite

Share

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.

Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K; adept™2 Investigators. Mahlangu JN, et al. Among authors: windyga j. J Thromb Haemost. 2015 Nov;13(11):1989-98. doi: 10.1111/jth.13141. Epub 2015 Oct 13. J Thromb Haemost. 2015. PMID: 26362483 Clinical Trial.

Cite

Share